BioXcel Therapeutics Inc (NASDAQ: BTAI) is -81.89% lower on its value in year-to-date trading and has touched a low of $0.52 and a high of $5.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BTAI stock was last observed hovering at around $0.53 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.53, the stock is -10.17% and -32.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing 1.54% at the moment leaves the stock -74.06% off its SMA200. BTAI registered -80.64% loss for a year compared to 6-month loss of -81.45%. The firm has a 50-day simple moving average (SMA 50) of $0.77206 and a 200-day simple moving average (SMA200) of $2.046965.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -18.92% gain in the last 1 month and extending the period to 3 months gives it a -57.93%, and is -18.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.84% over the week and 9.37% over the month.
BioXcel Therapeutics Inc (BTAI) has around 74 employees, a market worth around $21.77M and $2.40M in sales. Profit margin for the company is -4487.39%. Distance from 52-week low is 1.83% and -90.49% from its 52-week high. The company has generated returns on investments over the last 12 months (-372.34%).
The EPS is expected to grow by 69.95% this year
96.0 institutions hold shares in BioXcel Therapeutics Inc (BTAI), with institutional investors hold 27.31% of the company’s shares. The shares outstanding are 40.74M, and float is at 32.53M with Short Float at 2.14%. Institutions hold 21.83% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 2.99 million shares valued at $3.82 million. The investor’s holdings represent 9.6767 of the BTAI Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 2.21 million shares valued at $2.82 million to account for 7.1439 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.97 million shares representing 3.1438 and valued at over $1.24 million, while BLACKROCK INC. holds 1.4276 of the shares totaling 0.44 million with a market value of $0.56 million.
BioXcel Therapeutics Inc (BTAI) Insider Activity
The most recent transaction is an insider sale by Yocca Frank, the company’s Chief Scientific Officer. SEC filings show that Yocca Frank sold 355 shares of the company’s common stock on Sep 16 ’24 at a price of $0.69 per share for a total of $245.0. Following the sale, the insider now owns 14203.0 shares.
BioXcel Therapeutics Inc disclosed in a document filed with the SEC on Sep 16 ’24 that Mehta Vimal (CEO and President) sold a total of 1,982 shares of the company’s common stock. The trade occurred on Sep 16 ’24 and was made at $0.69 per share for $1367.0. Following the transaction, the insider now directly holds 51666.0 shares of the BTAI stock.
Still, SEC filings show that on Sep 16 ’24, Steinhart Richard I (Chief Financial Officer) disposed off 356 shares at an average price of $0.69 for $246.0. The insider now directly holds 6,204 shares of BioXcel Therapeutics Inc (BTAI).
